(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple ...
Lung cancer screening saves lives by detecting cancer early when it is most treatable. But what many people don’t realize is that the same low-dose CT scans used to screen for lung cancer can also ...
Researchers from Humana Healthcare Research and University of Chicago Medicine found that Medicare Advantage members with COPD and low medication adherence significantly improved their ...
Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33 (IL-33), an alarmin cytokine. This targeted approach is expected to reduce airway inflammation and ...
New FDA-approved medical treatments can be transformative for patients and families, often providing them with more years to live and an enhanced quality of life. 1 Delivering timely, high-quality ...
AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in chronic ...
Clinical Trials Arena on MSN
AstraZeneca’s COPD drug gains third Phase III win
Positive data from the MIRANDA trial follows the OBERON and TITANIA studies of tozorakimab in COPD.
COPD treatments aim to improve patients' quality of life, with options including medication, rehabilitation, and invasive procedures. Emphysema significantly impacts patients' daily activities due to ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In those with and those without emphysema, patients ...
AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win this year, offering ...
Reviewed by Ware Kuschner, MD, Professor of Medicine, Division of Pulmonary, Allergy, & Critical Care Medicine, Stanford University School of Medicine Among adults with chronic obstructive pulmonary ...
AstraZeneca (AZN) announced on Monday another late-stage trial win for its antibody therapy, tozorakimab, which is targeted at patients with chronic obstructive pulmonary disease, a respiratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results